Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLONYVAQ-CRC in Stage III MSS Colorectal Cancer
NCT07328087Phase 1Recruiting
- Sponsor
- Biogenea Pharmaceuticals
- Start
- Feb 2026
- Primary completion
- Dec 2030
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of COLONYVAQ-CRC in colorectal cancer (CRC), sponsored by Biogenea Pharmaceuticals. Primary endpoint: Incidence of Treatment-Emergent AEs/SAEs and Immune-Related AEs at 12 months. Started Feb 2026; status: recruiting.
02
Drugs
COLONYVAQ-CRC
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07328087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07328087.